Contineum Therapeutics CEO Carmine N. Stengone disposes of 2,500 common shares for $41,141.5
CTNM•CEO share transaction disclosed
- Contineum Therapeutics CEO and President Carmine N. Stengone sold 2,500 Class A common shares at $16.46 on Sep. 8, 2026.
- He acquired 2,500 Class A common shares at $1.01 via option exercise on the same day.
- Direct Class A common share holdings fell to 17,217 shares following the transactions.
